.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI04_Cefiderocol.Cefiderocol

Information

Cefiderocol is a novel siderophore cephalosporin antibiotic approved for the treatment of serious Gram-negative bacterial infections, including those caused by carbapenem-resistant organisms. It is administered intravenously and is indicated for use in complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP).

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers following intravenous administration.

References

1. Zhanel, GG, et al., & Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79(3) 271–289. DOI:10.1007/s40265-019-1055-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30712199

2. Sanz-Codina, M, et al., & Al Jalali, V (2024). Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers. The Journal of antimicrobial chemotherapy 79(12) 3281–3288. DOI:10.1093/jac/dkae359 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39373642

3. Zahr, N, et al., & Funck-Brentano, C (2022). Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients. Pharmaceutics 14(12) –. DOI:10.3390/pharmaceutics14122786 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36559279

Revisions

• 06/2025 initial generated model